News NICE aims to cut funding for Amgen lung cancer drug Lumykras Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.
News NICE delivers more good news for cervical cancer patients Hundreds of women with locally advanced cervical cancer are to be offered MSD's Keytruda on the NHS in England, thanks to new NICE guidance.
News NICE says Libtayo can be used for advanced cervical cancer New NICE guidance means that around 90 UK women with cervical cancer should be eligible for treatment with Regeneron's Libtayo each year.
News EFPIA report adds to pressures on EU drug pricing policy Pharma trade body EFPIA says access to new medicines is worsening across Europe, as it makes the socioeconomic case for spending more on novel drugs.
News Sanofi's type 1 diabetes-delaying drug cleared for NHS use People with early type 1 diabetes in England and Wales will soon be able to access Sanofi's Tzield, which can delay the need for insulin injections.
News AbbVie's migraine drug cleared for migraine attacks on NHS AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.